{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:45:35Z","timestamp":1787064335192,"version":"build-2736575974"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.prp.2021.153441","type":"journal-article","created":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T20:47:20Z","timestamp":1617914840000},"page":"153441","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Clinicopathologic features of unexpectedly HER2 positive breast carcinomas: An institutional experience"],"prefix":"10.1016","volume":"222","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0512-3574","authenticated-orcid":false,"given":"Carissa","family":"LaBoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8689-5508","authenticated-orcid":false,"given":"Kalliopi P.","family":"Siziopikou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9195-8035","authenticated-orcid":false,"suffix":"Jr.","given":"Luis Z.","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Pincus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2021.153441_bib0005","series-title":"WHO Classification of Tumours of the Breast","author":"Lakhani","year":"2012"},{"key":"10.1016\/j.prp.2021.153441_bib0010","series-title":"Rosen\u2019s Breast Pathology","author":"Rosen","year":"2014"},{"key":"10.1016\/j.prp.2021.153441_bib0015","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/modpathol.2016.175","article-title":"\u2019NOn-classical\u2019 HER2 FISH results in breast cancer: a multi-institutional study","volume":"30","author":"Ballard","year":"2017","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.prp.2021.153441_bib0020","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/modpathol.2017.171","article-title":"Clinical relevance and concordance of HER2 status in local and central testing-an analysis of 1581 HER2-positive breast carcinomas over 12 years","volume":"31","author":"Pfitzner","year":"2018","journal-title":"Mod. Pathol."},{"issue":"1_suppl","key":"10.1016\/j.prp.2021.153441_bib0025","doi-asserted-by":"crossref","first-page":"32S","DOI":"10.1177\/0272989X17743236","article-title":"Estimating breast cancer survival by molecular subtype in the absence of screening and adjuvant treatment","volume":"38","author":"Munoz","year":"2018","journal-title":"Med. Decis. Making"},{"key":"10.1016\/j.prp.2021.153441_bib0030","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/modpathol.2016.164","article-title":"Assessing HER2 testing quality in breast cancer: variables that influence HER2 positivity rate from a large, multicenter, observational study in Germany","volume":"30","author":"Ruschoff","year":"2017","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.prp.2021.153441_bib0035","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","volume":"31","author":"Wolff","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2021.153441_bib0040","doi-asserted-by":"crossref","first-page":"241","DOI":"10.5858\/arpa.2013-0953-SA","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"138","author":"Wolff","year":"2014","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.prp.2021.153441_bib0045","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical Oncology\/College of American pathologists clinical practice guideline focused update","volume":"142","author":"Wolff","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.prp.2021.153441_bib0050","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/his.13160","article-title":"Well-differentiated invasive breast cancers with equivocal HER2 immunohistochemistry: what is the yield of routine reflex in-situ hybridization testing?","volume":"70","author":"Bethune","year":"2017","journal-title":"Histopathology"},{"key":"10.1016\/j.prp.2021.153441_bib0055","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s10549-008-9893-8","article-title":"HER2 in well differentiated breast cancer: is testing necessary?","volume":"112","author":"Haines","year":"2008","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.prp.2021.153441_bib0060","doi-asserted-by":"crossref","first-page":"95","DOI":"10.4132\/jptm.2019.10.24","article-title":"Clinicopathologic characteristics of HER2-positive pure mucinous carcinoma of the breast","volume":"54","author":"Jang","year":"2020","journal-title":"J. Pathol. Transl. Med."},{"key":"10.1016\/j.prp.2021.153441_bib0065","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0960-9776(02)00273-4","article-title":"Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 International Study","volume":"12","author":"Bilous","year":"2003","journal-title":"Breast"},{"key":"10.1016\/j.prp.2021.153441_bib0070","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.5858\/arpa.2017-0265-RA","article-title":"Double-equivocal HER2 invasive breast carcinomas: institutional experience and review of literature","volume":"142","author":"Griffin","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.prp.2021.153441_bib0075","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMcibr1909386","article-title":"HER2 and breast cancer - a phenomenal success story","volume":"13","author":"Hayes","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prp.2021.153441_bib0080","doi-asserted-by":"crossref","first-page":"4455","DOI":"10.1002\/cncr.31657","article-title":"Optimal treatment of early stage HER2-positive breast cancer","volume":"124","author":"Pernas","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.prp.2021.153441_bib0085","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1002\/ijc.32418","article-title":"More options for adjuvant treatment of HER-2 positive breast cancer: how to choose wisely?","volume":"145","author":"Trapani","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.prp.2021.153441_bib0090","first-page":"48","article-title":"Treatment of HER-2 positive breast cancer","volume":"33","author":"Figueroa-Magalhaes","year":"2021","journal-title":"Breast. Curr Open Obstet. Gynecol."},{"key":"10.1016\/j.prp.2021.153441_bib0095","first-page":"128","article-title":"Frontiers in HER-2 positive breast cancer in 2020","volume":"23","author":"Peddi","year":"2014","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"10.1016\/j.prp.2021.153441_bib0100","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.breast.2018.03.006","article-title":"HER-2 positive breast cancer: current and new therapeutic strategies","volume":"39","author":"Escriva-de-Romani","year":"2018","journal-title":"Breast"},{"key":"10.1016\/j.prp.2021.153441_bib0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-020-0153-3","article-title":"Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond","volume":"6","author":"Costa","year":"2020","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.prp.2021.153441_bib0110","article-title":"HER2-positivity rates in breast cancer: no variation over time when clinicopathological features and testing are stable","volume":"26","author":"Beltjens","year":"2017","journal-title":"Eur. J. Cancer Care (Engl.)"},{"key":"10.1016\/j.prp.2021.153441_bib0115","doi-asserted-by":"crossref","first-page":"R69","DOI":"10.1186\/bcr2363","article-title":"Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline\/taxane-based chemotherapy","volume":"11","author":"Darb-Esfahani","year":"2009","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.prp.2021.153441_bib0120","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/sj.bjc.6604940","article-title":"Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours","volume":"100","author":"Tovey","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.prp.2021.153441_bib0125","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10549-014-2941-7","article-title":"Prognostic and biological significance of proliferation and HER2 expression in the luminal class of breast cancer","volume":"145","author":"Jerjees","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.prp.2021.153441_bib0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2015.11.010","article-title":"Prognostic risk factors for treatment decision in pT1a,b N0M0 HER2-positive breast cancers","volume":"43","author":"Musolino","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.prp.2021.153441_bib0135","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s10549-016-3878-9","article-title":"The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer","volume":"158","author":"van Ramshorst","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.prp.2021.153441_bib0140","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10549-017-4168-x","article-title":"Management of small T1a\/b breast cancer by tumor subtype","volume":"163","author":"Ignatov","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.prp.2021.153441_bib0145","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.prp.2017.09.027","article-title":"Pathobiology of HER 2 positive small invasive (T1a,b) breast cancer: \"A wolf in sheep\u2019s clothing\"","volume":"213","author":"Bezic","year":"2017","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.prp.2021.153441_bib0150","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00404-016-4016-y","article-title":"Brenda study group, do T1a breast cancers profit from adjuvant systemic therapy? A multicenter retrospective cohort study of 325 T1a-patients","volume":"294","author":"Wolters","year":"2016","journal-title":"Arch. Gynecol. Obstet."},{"key":"10.1016\/j.prp.2021.153441_bib0155","first-page":"575","article-title":"Accurately assessing HER2\/neu status in needle core biopsies of breast cancer in patients in the era of neoadjuvant therapy: emerging questions and considerations addressed","volume":"34","author":"D\u2019Alfonso","year":"2010","journal-title":"Diagn. Mol. Pathol."},{"key":"10.1016\/j.prp.2021.153441_bib0160","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/modpathol.3800496","article-title":"Interobserver agreement and reproducibility in classification of invasive breast carcinoma: an NCI breast cancer family registry study","volume":"19","author":"Longacre","year":"2006","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.prp.2021.153441_bib0165","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1053\/hupa.2002.32222","article-title":"Implications of pathologist concordance for breast cancer assessments in mammography screening from age 40 years","volume":"33","author":"Anderson","year":"2002","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.prp.2021.153441_bib0170","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/jclinpath-2016-203800","article-title":"Review of the national external quality assessment (EQA) scheme for breast pathology in the UK","volume":"70","author":"Rakha","year":"2017","journal-title":"J. Clin. Pathol."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033821001023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033821001023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T06:46:26Z","timestamp":1759733186000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033821001023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":34,"alternative-id":["S0344033821001023"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2021.153441","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinicopathologic features of unexpectedly HER2 positive breast carcinomas: An institutional experience","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2021.153441","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier GmbH. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"153441"}}